[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center].
At Nagoya Medical Center, 10 patients co-infected with HIV and HCV received peginterferon α (PEG-IFNα) plus ribavirin therapy. Three of the cases were HCV genotype 1b, 2 cases were HCV 3b, and 1 case each were 2b, 2c, 3a, 4a and 6n. Nine patients received anti HIV therapy from the beginning. In 5 of these patients, anti HIV therapy was modified when PEG-IFNα plus ribavirin treatment was started. Of the above, 7 patients completed the protocol. No patients had severe adverse effects. Sustained virological response was achieved in 1 of 4 (25%) of the patients with genotypes 1 or 4, and in 5 of 6 (83%) of the patients with other genotypes. PEG-IFNα plus ribavirin therapy is considered a safe and efficacious treatment for patients co-infected with HIV and HCV.
Department of Gastroenterology, Nagoya Medical Center, Japan. tsuzukit@nnh.hosp.go.jp
Tomoyuki
T
Tsuzuki
Hiroaki
H
Iwase
Masaaki
M
Shimada
Noboru
N
Hirashima
Yusuke
Y
Hibino
Nobumitsu
N
Ryuge
Masashi
M
Saito
Dai
D
Tamaki
Asako
A
Kamiya
Misaki
M
Yokoi
Yoshiyuki
Y
Yokomaku
Seiichiro
S
Fujisaki
Wataru
W
Sugiura
Hidemi
H
Goto
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D012254:Ribavirin / Q000008:administration & dosage*
D016898:Interferon-alpha; D012254:Ribavirin